ASH 2025 | What is on the horizon for the treatment of B-cell and T-cell ALL?
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the exciting developments in the treatment of acute lymphoblastic leukemia (ALL). Dr Short highlights potential therapeutic strategies on the horizon for both B-cell and T-cell ALL. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think there’s a lot of exciting things going on in the AML space. There’s a lot of new therapies, a lot of interest in menin inhibitors, for example, which is driving a lot of the excitement. In ALL, we’ve had a lot of recent advancements, such as blinatumomab consolidation, new CAR T-cell therapies, such as the obe-cel that was recently approved. So the big question is what’s going to be coming next in the ALL space...
I think there’s a lot of exciting things going on in the AML space. There’s a lot of new therapies, a lot of interest in menin inhibitors, for example, which is driving a lot of the excitement. In ALL, we’ve had a lot of recent advancements, such as blinatumomab consolidation, new CAR T-cell therapies, such as the obe-cel that was recently approved. So the big question is what’s going to be coming next in the ALL space. So I think a few potential areas of excitement. I think one is just there are some new interesting bispecific antibodies that are being evaluated. CD19 targeted therapies, so one by AstraZeneca, one by Merck, I think that are presented at ASH this year that are showing very exciting data. And I think, you know, the idea is that perhaps those could replace blinatumomab in the future, although we still need more efficacy data, safety data, and then ultimately the randomized studies need to be done. I think there’s also a lot of excitement or hope at least for what can be done in T-cell ALL. So, you know, really all the advancements in ALL, you know, in the last several years have been in B-cell ALL. We still struggle with managing patients with T-cell ALL. We don’t have as many good therapies. So we’re really hopeful that we’ll have, you know, new CAR T-cell therapies for T-cell ALL in the future, specifically, you know, CD7 CAR T-cells. And I think this is really an unmet need because we just don’t have good salvage therapies for these patients currently. So I’m very hopeful for, you know, new advancements in ALL, both in B-cell ALL and in T-cell ALL.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
